krn-7000 and Fibrosarcoma

krn-7000 has been researched along with Fibrosarcoma* in 1 studies

Other Studies

1 other study(ies) available for krn-7000 and Fibrosarcoma

Article	Year
Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2003, Aug-05, Volume: 100, Issue:16 Recent studies have revealed significant efficacy of the marine sponge glycolipid, alpha-galactosylceramide (alpha-GalCer), in treatment of experimental metastatic cancers, infections, and autoimmune diseases. However, the capacity of alpha-GalCer to prevent tumor development had never, to our knowledge, been evaluated in mouse models of chemical- and oncogene-dependent carcinogenesis. In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu transgenic mice, and spontaneous sarcomas in p53-/- mice. Weekly treatment of mice with alpha-GalCer maintained lymphoid tissue natural killer cell and T cell activation and elevated serum IFN-gamma and IL-4 concentrations. Consistent with the antimetastatic activity of alpha-GalCer, prevention of methylcholanthrene-induced sarcoma was IFN-gammaand tumor necrosis factor-related apoptosis-inducing ligand dependent, but not perforin-dependent. Taken together, our results demonstrate that NK1.1+alphabetaTCR+ cell-based immune therapy can inhibit primary tumorigenesis. Topics: Animals; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fibrosarcoma; Flow Cytometry; Galactosylceramides; Genes, p53; Humans; Interferon-gamma; Interleukin-12; Interleukin-4; Ligands; Methylcholanthrene; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neoplasms; Receptor, ErbB-2; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2003

Article

Year

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.

Proceedings of the National Academy of Sciences of the United States of America, 2003, Aug-05, Volume: 100, Issue:16

Recent studies have revealed significant efficacy of the marine sponge glycolipid, alpha-galactosylceramide (alpha-GalCer), in treatment of experimental metastatic cancers, infections, and autoimmune diseases. However, the capacity of alpha-GalCer to prevent tumor development had never, to our knowledge, been evaluated in mouse models of chemical- and oncogene-dependent carcinogenesis. In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu transgenic mice, and spontaneous sarcomas in p53-/- mice. Weekly treatment of mice with alpha-GalCer maintained lymphoid tissue natural killer cell and T cell activation and elevated serum IFN-gamma and IL-4 concentrations. Consistent with the antimetastatic activity of alpha-GalCer, prevention of methylcholanthrene-induced sarcoma was IFN-gammaand tumor necrosis factor-related apoptosis-inducing ligand dependent, but not perforin-dependent. Taken together, our results demonstrate that NK1.1+alphabetaTCR+ cell-based immune therapy can inhibit primary tumorigenesis.

Topics: Animals; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fibrosarcoma; Flow Cytometry; Galactosylceramides; Genes, p53; Humans; Interferon-gamma; Interleukin-12; Interleukin-4; Ligands; Methylcholanthrene; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neoplasms; Receptor, ErbB-2; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2003